FDA, EMEA accept Amevive filing

Biogen (BGEN) said that its license application for Amevive alefacept to treat moderate to severe psoriasis was accepted for filing by the FDA and EMEA. In August, BGEN submitted a Common Technical Document for FDA and EMEA approval of the recombinant human LFA-3 fusion protein that binds CD2. BGEN was up $0.82 to $53.76 on Friday. ...